Navigation Links
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Date:12/12/2007

Data Suggest Continued Improvement in Motor Function at 24 Months

SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these 'responders' at 12 months was 46 percent. Today it was reported that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52 percent at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort). More specifically, there was a statistically significant improvement in the primary endpoint compared to baseline (p<0.001) defined as the reduction in Parkinson's symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 continues to appear safe and well-tolerated, with no treatment-related or surgically-related serious adverse events reported for any of these patients. These data were presented today at the World Congress of Parkinson's Disease by Raymond T. Bartus, Ph.D., Ceregene's executive vice president of clinical and preclinical R&D and chief operating officer.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , CHICAGO, Nov. 30 Breas... be a highly sensitive imaging technique for the d...ficult to diagnose breast cancer. BSGI is a molecu...independent of tissue density and discover very ea... today at the annual meeting of the Radiological S...
(Date:11/30/2009)..., , PRINCETON, N.J., Nov. 30 /PRNewswire...nnounced that it will present at the Piper Jaffray...December 2, 2009 at 1:30 p.m. (ET). Investors may....covance.com . In order to register and download ...arly. ,, Covance, with headquarters in Princeto...
(Date:11/30/2009)..., , TORONTO, Nov. 30 The S...on Inc. ("Patheon" or the "Company") (TSX: PTI) an...n Holdings, LLC (collectively, "JLL"), today annou...settlement agreement in respect of the pending leg...ment provides among other things that: ,, unti...
Breaking Medicine Technology:Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2Patheon and JLL Partners Announce Litigation Settlement 2Patheon and JLL Partners Announce Litigation Settlement 3STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 1STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 2STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 3STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 4Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 1Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 2Hair Loss Website Launches Program for Children 54943 1Hair Loss Website Launches Program for Children 54943 2
... YORK, Aug. 7 Bristol-Myers Squibb Company,(NYSE:...g Administration,(FDA) has accepted, for filing an...cation (sBLA) for ORENCIA(R) (abatacept) for the t...athic arthritis (JIA) who have had an,inadequate r...matic drugs,(DMARDs) such as methotrexate (MTX) or...
...VERS, Mass., Aug. 7 The results of a pilot study,...tritionj.com ) suggest that,children with attentio...t,from daily supplementation of high levels of pur... that children who consumed between 8 and 16,grams...tty acids found in,fish oil) showed significant im...
Other Medicine Technology:ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 2ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 3ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 4Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD 2
(Date:12/1/2009)..., TORONTO, Dec. 1 /PRNewswire/ - Sentinelle Med...ils and 4D advanced visualization software, extend...ear,s Radiological Society of North America (RSNA)... (Booth 5800, Hall A). ,, With the unique Vangu...able Coil Geometry(TM), Sentinelle,s line of breas...
(Date:12/1/2009)... Caregiving: Ready or Not helps... ones , Cincinnati, Ohio ... mission—a mission to help families understa... , ,“While we hope our loved ones live long,... many people require care at some point, and their...
(Date:12/1/2009)... Free hearing aids will be give...al Texas. , Austin, TX (P...arlifeagain.com ), a professional hearing healthca...e hearing impaired and their families, announced t...dquo; holiday giveaway. Each year, Estes Audiolog...
(Date:12/1/2009)... Anthony M. Marlon, MD was elec...uo;Stemedica”) Board of Directors at the Com... (PRWEB) December 1, 2009 -- Ant...ell Technologies , Inc. (“Stemedica”) ... 20th Board Meeting. Roger J. Howe, PhD, Executive...
(Date:12/1/2009)... , NEWPORT BEACH, Calif., Dec. 1 /PRNewswire/...de that insurers will reimburse them for the $20 c...r for ,going under, for surgery. ,, Anesthesiol... monitoring is to avoid postop dementia from routi...ists have not heard the ,avoid over-medication, me...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 2Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 3Health News:Aging Expert's New Book Helps Boomers Address Challenges of Caregiving 2Health News:Estes Audiology Offers the Gift of Hearing to Celebrate the Holiday Season 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 3Health News:5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed 2
...MedCath Corporation,(MedCath) (Nasdaq: MDTH ), it...Dayton, Ohio) jointly announced today that the par...uant to which Good Samaritan,Hospital will acquire...ustomary non-competition obligations. The,transact...
...ting needed screenings for breast and cervical tum...-- A new review of 32 studies suggests that obese ...ly than others to skip screenings for breast and c...seems to have no significant effect on colorectal ...
...ad-to-head with your child,can be more stacked tha...for some extra reading at bedtime and, before you ...th a bait-and-switch that you can,t refuse.,Well, ...t., Where,s F. Lee Bailey when you need him?" so w...
... in Singapore to develop future lab-on-chip ...INGAPORE, March 24 Following the,success of the e...onal,University Hospital of Singapore, Veredus Lab...d detection of,all major influenza types at the po...
...their lives in the spring, doctors say , ,...eople view spring as a time of renewal and hope, t...s occur each year in April and May, notes the Amer...ow that suicide is the 11th leading cause of death...
...es much more than a mechanical fix for ailing pati...) -- In dogs with damaged hearts, implanted pacema...and the activity of a number of proteins crucial ...ogical effects a pacemaker has on the heart. This ...
Other Medicine News:Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:HOW TO UNSPOIL YOUR CHILD FAST: Harvard Medical School Psychologist Writes Book to Guide and Motivate Parents and Support the Children's Defense Fund 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 3Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Pacemakers Change Biology of the Heart 2
Demineralized Cortical Powder, DGC40
StealthStation TRIA Surgical Navigation Technology
... navigation system for ENT, cranial and spine proc...ively, critical zones visible during tracking. Ima...utton freezes image, snapshot can be taken of froz... of the microscope, low profile receiver attachmen...
Octafix
Medicine Products: